secwatch / observer
8-K filed May 15, 2024, 7:59 PM ET CIK 0001261249
earnings confidence high sentiment positive materiality 0.75

Agile Therapeutics Q1 net revenue $5.7M (+58% QoQ); GAAP net income of $1.3M

AGILE THERAPEUTICS INC

2024-Q1 EPS reported $0.28 revenue$5,716,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AGILE THERAPEUTICS INC reported three months ended March 31, 2024 results: revenue $5.7 million, net income $1.3 million, EPS $0.28 per share.

Period
three months ended March 31, 2024
Revenue
$5.7 million
Net income
$1.3 million
EPS
$0.28 per share
Result
reported results
Exact text from the filing
Net Revenue: In the first quarter 2024, the Company realized net product sales revenue of $5.7 million, a 58% increase from the fourth quarter 2023 and an increase of 50% as compared to the first quarter of 2023 net revenue of $3.8 million. ● Cost of Goods Sold (COGS) : Cost of goods sold, which consists of direct and indirect costs related to the manufacturing of Twirla, were $1.7 million for the first quarter 2024 compared to the $2.2 million for the fourth quarter 2023 and compared to the $2.0 million for the first quarter 2023. ● Total operating expenses: Total GAAP operating expenses were $6.8 million for the quarter ended March 31, 2024, compared to the $5.5 million for the fourth quarter 2023 and compared to $8.5 million for the comparable period in 2023 – a decrease of 20%. ● GAAP Net income (loss): GAAP net income was $1.3 million, or $0.28 per share, for the quarter ended March 31, 2024, compared to a GAAP net loss of $4.5 million, or $1.51 per share, for the fourth quarter 2
View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR
accession 0001558370-24-008293
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.